Toronto, November 28, 2025 (Globe NewsWire) – Quantum biopharma ltd. (NASDAQ:QNTM) (CSE:QNTM) (Fra:0K91)Quantum BioPharma“, is pleased to announce that national television network CTV News' flagship investigative program W5 has aired the second part of a three-part series on Quantum Biopharma and the company's allegations of stock market manipulation.
Award-winning CTV News journalist and W5 investigative reporter John Woodward covers the highlights of part two of the series in an article entitled “Something Was Wrong”: Inside a Canadian Biotech Firm's Struggle to Prove 'Stock Fake'. The largest banks in Canada are CIBC and RBC.
The second three-part W5 investigative series can be viewed today on CTV News at: W5: Quantum BioPharma seeks $700 million in stock counterfeit lawsuit.
Part 1 can be viewed at: W5: Multiple Sclerosis Research Derailed by Stock Market Rigging: Lawsuit.
Quantum BioPharma Chief Executive Officer Zeeshan Saeed commented: “We commend W5 for its important investigation into the illegal but little-known practice of stock counterfeiting and some of its detrimental consequences for retail investors. Our goal has always been to create Lucid-MS, a potential game-changing drug that has been shown in animal studies to stop and even reverse the degradation of nerve cells (a hallmark of multiple sclerosis), restoring mobility and control to the body, unlike any cure today, for the benefit of the millions of people around the world who are courageously living with this progressive and debilitating disease, we hope to prevent other companies, their shareholders and beneficiaries from going through what we went through.”
Quantum BioPharma Co-Executive Chairman Anthony Durkac added: “The basis of our $700 million lawsuit against CIBC and RBC is that we allege that Canadian stock trading data clearly shows stock tampering on a massive scale to manipulate Quantum BioPharma's share price. It is the responsibility of banks and brokers to act as gatekeepers and ensure that their clients and their traders do not violate trading rules and regulations. or are not engaging in illegal activities such as stock counterfeiting. We allege that at least 16 million illegal and fraudulent orders originated from Canadian bank platforms.”
For more information visit: www.quantumbiopharma.com.
About the company “Quantum BioPharma”
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company focused on developing a portfolio of innovative assets and biotechnology solutions to treat complex neurodegenerative, metabolic and alcohol use disorders using drug candidates in various stages of development. Through its wholly owned subsidiary Lucid Psycheceuticals Inc. (“Clear“), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical that has been shown to prevent and reverse myelin degradation, a major mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and marketed its over-the-counter version to Celly Nutrition Corp. (“Celly Nutrition“), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains a 19.86% stake in Unbuzzd Wellness Inc. as of September 30, 2025. www.unbuzzd.com. Agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% on unbuzzd™ sales until the total payment to Quantum BioPharma reaches US$250 million. Once the amount reaches $250 million, the royalty will drop to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical applications. Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial real estate. For more information visit www.quantumbiopharma.com..
Forward-Looking Information
This press release contains certain “forward-looking statements” within the meaning of applicable securities laws. Any statements that express or involve discussions of projections, expectations, beliefs, plans, goals, assumptions or future events or results (often, but not always, identified by words or phrases such as “believes,” “hopes,” “asserts,” “expects,” “further,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “which,” or “will” and similar expressions) are not statements of historical facts and may be predictive in nature. statements. Forward-looking information contained herein includes, but is not limited to, statements regarding: the Company's ongoing litigation against major financial institutions; the potential outcome or value of a judgment; expectations regarding whistleblowing submissions and related rewards; continuation of market integrity initiatives; future business results and potential acquisitions.
In making forward-looking statements in this press release, the Company has made several significant assumptions, including, but not limited to: the ability to obtain and verify whistleblower evidence; timing and outcome of the trial; resolution of ongoing trials on preferential terms, availability and sufficiency of funding for trials; continued compliance with regulatory requirements and market stability of the Company's activities.
The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management as of the date the statements are made and are subject to a number of risks and uncertainties. Accordingly, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The above lists of forward-looking statements and assumptions are not exhaustive. Because forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently expected or implied by such forward-looking statements due to a number of factors and risks. These include: unfavorable outcome of lawsuits; receipt and reliability of whistleblower reports; changes in applicable laws and regulations; actions of third parties involved in the alleged manipulation; evolving market dynamics; the sufficiency of proceeds from future litigation to fund the Company's whistleblower fees; continued ability to obtain adequate litigation funding; limited future growth opportunities and dependence on key personnel.
Except as required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions or other factors change.
The reader is urged to refer to additional information regarding Quantum BioPharma, including its annual information form, which can be found on SEDAR+ at: www.sedarplus.ca and in the EDGAR section of the SEC website at: www.sec.gov for a more complete discussion of such risk factors and their potential consequences.
Contacts:
Quantum BioPharma LLC
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board of Directors
E-mail: [email protected]
Phone: (833) 571-1811.
Investor Relations
Investor Relations: [email protected]
General questions: [email protected]
